#3 - Regeneron (NASDAQ:REGN)
Regeneron (NASDAQ:REGN) is making news for its part in treating President Trump. However, that is only part of the story. Regeneron first made news by announcing it was working with Sanofi (NYSE:SNY) to test Kevzara – which is used to treat rheumatoid arthritis – as a potential treatment for boosting the immune system of Covid-19 patients. Unfortunately, the companies experienced disappointing results in its Phase 2 trial.
However, Regeneron was already working on a separate project. This was the “cocktail” that President Trump received. The antiviral cocktail, REGN-COV2, only began clinical trials in June. So even though President Trump’s initial immune response appears favorable, it’s far too early to tell if this treatment will receive FDA approval. Nevertheless, the company is getting more requests via the FDA’s “compassionate use” authorization.
REGN stock is up 56% for the year but is only up 3% on news of President Trump’s treatment. This is consistent with the company’s history in which the company has shown a strong average annual revenue growth of 22%, but it has not translated into the company’s stock price.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More - Current Price
- $976.96
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 15 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $981.71 (0.5% Upside)
